Effectiveness and safety profile of fluticasone propionate 0.05% in paediatric dermatoses

Authors

  • Atul Dilip Mohankar Department of Dermatology, Shree Balaji Institute of Medical Sciences (SBIMS), Raipur, Chhattisgarh, India
  • Mayank Sinha Department of Dermatology, Shree Balaji Institute of Medical Sciences (SBIMS), Raipur, Chhattisgarh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241250

Keywords:

Fluticasone propionate, Paediatric dermatoses, Anti-nuclear antibody

Abstract

Background: Topical corticosteroids are effective in the treatment of paediatric dermatoses. However, concerns regarding possible side effects of topical steroids have limited the use of moderate-potency corticosteroids in children. Objective of this study was to evaluate the effectiveness and safety profile of fluticasone propionate 0.05% cream in paediatric dermatoses.

Methods: A total 84 children between 6 months to 12 years of age with moderate to severe  dermatoses (< or =30% body surface area) were treated with fluticasone propionate 0.05% cream  twice daily for 4 to 6 weeks. Adverse effects of topical steroids were analyzed.

Results: Out of total 84 patients, 46 (54.76%) patients completely cured at 4 weeks and 23 (27.38%) patients at 6 weeks, while remaining 11 (13.10%) patients showed moderate improvement, 4 were lost for follow up after 2 weeks. Only in 2 patients we observed hypopigmentatipon of skin, otherwise in all patients no significant side effect were seen.

Conclusions: Fluticasone propionate 0.05% cream appears to be quite safe for the treatment of moderate to severe dermatoses for up to 4 to 6 weeks in children less than 12 years of age.

References

Thappa DM. Common skin problems in children. In J Paediatr. 2002;69:701-06.

Sardana K, Mahajan S, Sarkar R, Mendiratta V, Bhushan P, Koranne RV, et al. The spectrum of skin disease among Indian children. Paediatr Dermatol. 2009;26(1):6-13.

Bonthu I, Purushothaman S, Vukkadala ND. Clinico-etiological study of paediatric dermatoses in tertiary health care hospital in East-coast Andhra Pradesh, India. Int J Res Dermatol. 2020;6(4):456-62.

Jain N, Khandpur. Paediatric dermatoses in India. Indian J Dermatol Venereol Leprol. 2010;76:451-54.

Gardman J, Wolthers OD. Short term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatr. 2007;96(8):1233-7.

Friedlander SF, Hebert AA, Allen DB. Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46(3):387-93.

Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of metabolites. Drug Metab Dispos. 2006;34(2):225-33.

Kanwar AJ, De D. Lichen planus in childhood: Report of 100 cases. Clin Exp Dermatol. 2010;35(3):257-62.

Handa S, Sahoo B. Childhood lichen planus: A study of 87 cases. Int J Dermatol. 2002;41(7):423-7.

Podder I, Agarwall K, Anurag A. Pattern and distribution of pediatric dermatoses and their association with parental socioeconomic status: A single-center experience from India. Ind J Paedia Dermatol. 2022;23(3):214-20.

Lebwohl M. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Cutis. 1996;57(2_Suppl):62-8.

Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46(3):387-93.

Downloads

Published

2024-04-30

How to Cite

Mohankar, A. D., & Sinha, M. (2024). Effectiveness and safety profile of fluticasone propionate 0.05% in paediatric dermatoses. International Journal of Research in Medical Sciences, 12(5), 1619–1621. https://doi.org/10.18203/2320-6012.ijrms20241250

Issue

Section

Original Research Articles